# DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Source: https://onco.cc/trials/nct06221748/  
OnCo record `nct06221748` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Disitamab vedotin and Cadonilimab in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., now recruiting.

## Summary

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy is a phase 2/3 interventional study registered as NCT06221748 by RemeGen Co., Ltd., with 90 participants planned, started 2024-02-22 and due to reach its primary completion in 2026-12. Interventions recorded: Disitamab Vedotin Injection, Cadonilimab Injection and Paclitaxel Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06221748
- Phase: 2/3
- Setting: A Randomized，Multicenter, Open-Label，Phase II/III Study to Evaluate the Safety and Efficacy of Disitamab Vedotin Combined With Cadonilimab in Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma Who Have Progressed on r First-line Therapy
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06221748: https://clinicaltrials.gov/study/NCT06221748

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct06221748.json